Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Recurrence Risk Stratification in Clear Cell Renal Cell Carcinoma Using TNM 2017 and WHO/ISUP Grade

KOSUKE HAMADA, TAKESHI YAMASAKI, CHISATO OHE, NOZOMI TSUJIO, SHOMA YAMAMOTO, TAISUKE MATSUE, NAO YUKIMATSU, TAIYO OTOSHI, MINORU KATO, KATSUYUKI KURATSUKURI, MASANORI SHIOHARA, KENICHI KOHASHI and JUNJI UCHIDA
Anticancer Research May 2026, 46 (5) 2743-2751; DOI: https://doi.org/10.21873/anticanres.18154
KOSUKE HAMADA
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI YAMASAKI
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tysy-y{at}mx5.canvas.ne.jp
CHISATO OHE
2Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
3Department of Surgical Pathology, Hyogo Medical University, Hyogo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOZOMI TSUJIO
2Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHOMA YAMAMOTO
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAISUKE MATSUE
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAO YUKIMATSU
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAIYO OTOSHI
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MINORU KATO
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUYUKI KURATSUKURI
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASANORI SHIOHARA
2Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENICHI KOHASHI
2Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNJI UCHIDA
1Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: To re-evaluate established recurrence risk models for clear cell renal cell carcinoma (ccRCC) using the tumor, node, metastasis (TNM) 2017 classification and the World Health Organization/International Society of Urological Pathology (WHO/ISUP) grading system, and to perform an exploratory analysis of whether these updates improve the predictive accuracy of recurrence risk models.

Patients and Methods: We retrospectively analyzed 295 patients who underwent surgery for non-metastatic ccRCC at Osaka Metropolitan University Hospital between 2013 and 2020. Pathological features were re-evaluated using both the TNM 2009 and TNM 2017 classifications, as well as the Fuhrman and WHO/ISUP grading systems. We examined the frequency of pathological upstaging to pT3a and compared recurrence predictions across grading systems. In addition, we assessed recurrence risk stratification using the Leibovich 2003 and 2018 models with updated pathological classifications. Recurrence-free survival (RFS) was assessed using Kaplan–Meier analysis, and prognostic accuracy was evaluated using Harrell’s concordance index (C-index).

Results: Among cT1 cases, pathological upstaging to pT3a occurred more frequently according to TNM 2017 (18.9%) than TNM 2009 (16.0%). TNM 2017 showed superior prognostic performance for predicting recurrence in cT1 tumors (C-index, 0.748 vs. 0.726). The WHO/ISUP grade demonstrated greater predictive accuracy than the Fuhrman grade (C-index, 0.817 vs. 0.737). The C-index of the Leibovich 2003 model improved from 0.812 (TNM 2009 plus Fuhrman classification) to 0.834 (TNM 2017 plus the WHO/ISUP classification). The highest predictive accuracy was achieved using the Leibovich 2018 model (C-index, 0.870).

Conclusion: Re-evaluation using TNM 2017 and WHO/ISUP grading was associated with improved predictive accuracy of recurrence risk models for localized ccRCC and may aid postoperative risk stratification.

Keywords:
  • Renal cell carcinoma
  • recurrence
  • re-evaluation
  • risk
  • grade
  • TNM
  • Received February 13, 2026.
  • Revision received March 10, 2026.
  • Accepted March 17, 2026.
  • Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 46 (5)
Anticancer Research
Vol. 46, Issue 5
May 2026
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Ed Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Recurrence Risk Stratification in Clear Cell Renal Cell Carcinoma Using TNM 2017 and WHO/ISUP Grade
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
16 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Recurrence Risk Stratification in Clear Cell Renal Cell Carcinoma Using TNM 2017 and WHO/ISUP Grade
KOSUKE HAMADA, TAKESHI YAMASAKI, CHISATO OHE, NOZOMI TSUJIO, SHOMA YAMAMOTO, TAISUKE MATSUE, NAO YUKIMATSU, TAIYO OTOSHI, MINORU KATO, KATSUYUKI KURATSUKURI, MASANORI SHIOHARA, KENICHI KOHASHI, JUNJI UCHIDA
Anticancer Research May 2026, 46 (5) 2743-2751; DOI: 10.21873/anticanres.18154

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Recurrence Risk Stratification in Clear Cell Renal Cell Carcinoma Using TNM 2017 and WHO/ISUP Grade
KOSUKE HAMADA, TAKESHI YAMASAKI, CHISATO OHE, NOZOMI TSUJIO, SHOMA YAMAMOTO, TAISUKE MATSUE, NAO YUKIMATSU, TAIYO OTOSHI, MINORU KATO, KATSUYUKI KURATSUKURI, MASANORI SHIOHARA, KENICHI KOHASHI, JUNJI UCHIDA
Anticancer Research May 2026, 46 (5) 2743-2751; DOI: 10.21873/anticanres.18154
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Laparotomy After Total Pelvic Exenteration: Current Status and Techniques for Ileal Conduit Preservation
  • Pregabalin for Opioid-resistant Neuropathic Pain in Bone Metastases
  • Life-threatening Pneumonitis Induced by Osimertinib Monotherapy as a First-line Treatment for Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer: A Retrospective Case-series Study
Show more Clinical Studies

Keywords

  • Renal cell carcinoma
  • recurrence
  • re-evaluation
  • risk
  • grade
  • TNM
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire